Update on the optimal use of bortezomib in the treatment of multiple myeloma

@inproceedings{Mohan2017UpdateOT,
  title={Update on the optimal use of bortezomib in the treatment of multiple myeloma},
  author={Meera Mohan and Aasiya Matin and Faith Elizabeth Davies},
  booktitle={Cancer management and research},
  year={2017}
}
The proteasome inhibitor (PI) "bortezomib" has now been in routine clinical practice for over a decade. It is now considered an important backbone therapy for all stages of the disease, and data continue to grow to support its use in newly diagnosed patients, relapsed and relapsed/refractory disease, maintenance therapy, high risk, and renal failure. Much has been learnt about the most clinically effective way of delivering therapy, with patients often benefiting more from a triplet bortezomib… CONTINUE READING